Recent Developments in Contrast Media

Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast agents accumulate in tissues inside patients. This has raised concern because prolonged, elevated levels of gadolinium in the body may cause a nephrogenic systemic fibrosis in patients with severe kidney disease. Adding to this concern were three studies in 2015, which raised new gadolinium safety concerns after it was found the agent also accumulates in the brain

New Generation Contrast Media and Renal Saftey Asian Journal of Medical Radiological Research

Gadolinium Based Contrast Media Market Size 2023, Forecast By 2032

Cardiac MRI Contrast Agents Carry Low Risk of Adverse Events

Iodine Contrast Media Market , Share and Current Insights

Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma, Journal of Nanobiotechnology

Contrast Media Market - Trends, Size, Growth

New Gadolinium-Free MRI Contrast Agent Advances Safer Patient Care

AI Software Confirms the Results of a Large Scale Comparison of Gadoteridol and Gadavist Injection

New strategies towards advanced CT contrast agents. Development of neutral and monoanionic sulfur-bridged W(v) dimeric complexes - Dalton Transactions (RSC Publishing)